

Tomohiro Sakamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10027550/publications.pdf>

Version: 2024-02-01

24
papers

762
citations

1040056

9
h-index

610901

24
g-index

24
all docs

24
docs citations

24
times ranked

1026
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). <i>Clinical Lung Cancer</i> , 2022, 23, e257-e263.	2.6	10
2	Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. <i>European Journal of Cancer</i> , 2022, 162, 99-106.	2.8	30
3	Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event. <i>Molecular and Clinical Oncology</i> , 2022, 17, .	1.0	2
4	Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100107.	1.1	15
5	Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1261-1268.	1.3	12
6	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). <i>BMC Cancer</i> , 2021, 21, 1121.	2.6	3
7	METex14 Skipping Testing Guidance for Lung Cancer Patients: The Guidance from the Biomarker Committee, the Japan Lung Cancer Society. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 361-370.	0.1	3
8	BRAF V600E-mutated combined large cell neuroendocrine carcinoma and adenocarcinoma responding to targeted therapy. <i>BMJ Case Reports</i> , 2021, 14, e243295.	0.5	3
9	Multiplex gene panel testing for lung cancer patients. <i>Pathology International</i> , 2020, 70, 921-931.	1.3	29
10	Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 813-824.	27.0	505
11	Therapeutic impact of mutation subtypes and concomitant STK11 mutations in KRAS-mutated non-small cell lung cancer (NSCLC): A result of nationwide genomic screening project (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9589-9589.	1.6	10
12	Large scale clinico-genomic analyses among patients with BRAF-mutated non-small cell lung cancers (NSCLC) identified by nationwide genomic screening project (LC-SCRUM-Japan).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9590-9590.	1.6	2
13	Phase II study of tepotinib in NSCLC patients with METex14 mutations.. <i>Journal of Clinical Oncology</i> , 2019, 37, 9005-9005.	1.6	49
14	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9125-TPS9125.	1.6	3
15	Nivolumab-induced cholangitis in patients with non-small cell lung cancer: Case series and a review of literature. <i>Molecular and Clinical Oncology</i> , 2019, 11, 439-446.	1.0	16
16	An onion farmer with a case of hypersensitivity pneumonitis caused by <i>Aspergillus niger</i> . <i>Respiratory Medicine Case Reports</i> , 2018, 23, 60-62.	0.4	6
17	Acute-phase reaction induced by zoledronate and its effect on prognosis of patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 122, 200-205.	2.0	10
18	Development of fever following first administration of zoledronate as a prognostic factor in advanced non-small cell lung cancer patients with bone metastases. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1000-1004.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Frequency of Epidermal Growth Factor Receptor Mutation in Smokers with Lung Cancer Without Pulmonary Emphysema. <i>Anticancer Research</i> , 2017, 37, 765-772.	1.1	6
20	DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair. <i>Yonago Acta Medica</i> , 2017, 60, 9-15.	0.7	20
21	A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer. <i>International Journal of Oncology</i> , 2015, 46, 1473-1480.	3.3	9
22	Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase-inhibitory fluoropyrimidine in EGFR-mutated lung adenocarcinoma: Retrospective and in vitro studies. <i>International Journal of Oncology</i> , 2015, 46, 989-998.	3.3	3
23	A new rapid method for detecting epidermal growth factor receptor mutations in non-small cell lung cancer. <i>Oncology Reports</i> , 2015, 33, 1040-1048.	2.6	7
24	Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: Implication of EGFR tyrosine kinase inhibitors. <i>International Journal of Oncology</i> , 2014, 44, 685-692.	3.3	6